A5048336025- Health Systems, Economic Evaluations, Quality of Life
- Cerebral Palsy and Movement Disorders
- Clinical Nutrition and Gastroenterology
- Cardiac, Anesthesia and Surgical Outcomes
- Botulinum Toxin and Related Neurological Disorders
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Colorectal Cancer Surgical Treatments
- Helicobacter pylori-related gastroenterology studies
- Urinary Tract Infections Management
- Inflammatory Bowel Disease
- Parathyroid Disorders and Treatments
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Biotechnology and Related Fields
- Myasthenia Gravis and Thymoma
- Attention Deficit Hyperactivity Disorder
- Pancreatitis Pathology and Treatment
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Enhanced Recovery After Surgery
- Rheumatoid Arthritis Research and Therapies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- IgG4-Related and Inflammatory Diseases
- Anesthesia and Pain Management
Canisius-Wilhelmina Ziekenhuis
2025
Utrecht University
2024
Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses significant economic burden. The Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects Background Methotrexate (AMPLE) trial was head-to-head, randomized study comparing abatacept serum anti-citrullinated protein antibody (ACPA)-positive patients, increasing efficacy across ACPA quartile levels. aim this evaluate the...
Non-dystrophic myotonias (NDMs) comprise muscle chloride and sodium channelopathies due to genetic defects of the CLCN1- SCN4A-channels. No licensed antimyotonic treatment has been available until approval mexiletine (NaMuscla®) for adult patients by EMA in December 2018. This Delphi panel aimed understand how outcomes pivotal phase III Mexiletine study (MYOMEX) translate real world practice investigate health resource use, quality life natural history NDM support economic modelling...
Introduction: Botulinum toxin type A (BoNT-A) is used in the management of lower limb spasticity children, which affects more than 2.5 million children worldwide. BoNT-A aims to improve active function and prevent or delay future musculoskeletal complications. The objective was evaluate relative efficacy safety different manage absence head-to-head evidence. Methods: systematic literature review conducted March 2016 identify all relevant randomized controlled trials. evidence base...
<title>Abstract</title> <bold>Background:</bold> Wild-type and hereditary transthyretin-mediated amyloidosis (ATTRwt ATTRv amyloidosis, respectively) are progressive, fatal diseases with a broad range of clinical presentations multisystem effects. Despite having higher prevalence, ATTRwt is less well characterized due to its non-hereditary nature, relatively poorer disease awareness delays diagnosis. Understanding natural history has evolved in recent years, but this largely based on...
<h3>Introduction</h3> Immunonutrition (IN) containing arginine has been demonstrated to decrease complications as well length of hospital stay in surgical patients numerous meta-analyses randomised clinical trials (Drovers <i>et al</i> 2011; Cerantola 2011). Its impact on costs already assessed gastrointestinal (GI) cancer surgery based Swiss, US, Italian and German (Mauskopf Chevrou-Séverac Braga 2005; Senkal 1999). The objective this study is assess whether IN a cost-effective option...
Background: Botulinum toxin type A (BoNT-A) is used in the management of pediatric lower limb spasticity to improve function and prevent or delay musculoskeletal complications. In absence head-to-head evidence, this meta-analysis evaluated relative efficacy safety different BoNT-A formulations management.